Project Grant R21AG091155
Award Date 2/15/26
Completion Date 2/14/28
Dollars Obligated $428K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Albany, NY 12208, USA
Similar Awards
- The National Institute on Aging awarded a $1,931,965 Project Grant (CFDA 93.866 - Aging Research) to the Regenerative Research Foundation, a non-profit organization in Albany, New York. The purpose of this federal grant is to develop and validate a novel human induced pluripotent stem cell (iPSC) model that incorporates cerebral cortical neurons, glia, vascular endothelial cells, and microglia to study cerebrovascular interactions in Alzheimer's disease-related dementias (ADRD). The R61 phase of...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Massachusetts General Hospital a $1.58 million Project Grant on March 15, 2025, under the Aging Research program (CFDA 93.866) to conduct research characterizing microvascular impairment in adults with elevated genetic risk for Alzheimer's disease. The research initiative, which extends through January 31, 2030, investigates the physiological mechanisms through which the apolipoprotein E-epsilon 4 (APOE-E4) allele—the...
- This Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $10,847,672 to the J. David Gladstone Institutes, a non-profit biomedical research organization, to investigate the vascular-immune mechanisms underlying cerebral amyloid angiopathy (CAA) and Alzheimer's disease pathology. The research aims to elucidate the key microglial mechanisms regulating the formation of vascular CAA versus parenchymal amyloid-beta plaques, define single-cell and...
- Grant Award Summary Vanderbilt University Medical Center received a $1.47 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) for a five-year research project running from January 1, 2026 through December 31, 2030. The award funds research titled "Probing Mechanistic Links Between Endothelial Aging and Dementia," which aims to advance understanding of vascular contributions to cognitive impairment and dementia (VCID) through the...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded J. David Gladstone Institutes a Project Grant totaling $804,450 (awarded June 1, 2025, with completion targeted for March 31, 2030) under the Aging Research program (CFDA 93.866) to conduct biomedical research investigating the molecular mechanisms underlying Apolipoprotein E4 (APOE4)-driven pathogenesis in Alzheimer's disease (AD). The research will focus on targeting the growth factor protein NELL2 (Neural...
- Federal Grant Award Summary Massachusetts General Hospital (The General Hospital Corporation) received a $3.17 million Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective February 15, 2026 through February 14, 2030. The award funds development and evaluation of cell therapy approaches to treat Alzheimer's disease by restoring inhibitory neural circuit function. The research focuses on transplanting embryonic mouse medial ganglionic...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded a $470,000 project grant to Trustees of Tufts College (doing business as Tufts University School of Medicine) for research titled "Elucidating the Interplay Between AD Genetic Variants Using Human iPSC-Derived Brain Cells." The award, issued under the Aging Research program (CFDA 93.866) on February 1, 2026, with an ultimate completion date of January 31, 2028, supports biomedical research directed toward...
- This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
- This federal Project Grant award, totaling $2,683,965.00 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the establishment of a human microphysiological system to elucidate cellular mechanisms underlying vulnerability to Alzheimer's disease (AD). The grant recipient, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare...
- This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...